🔗 Share this article Patients Stopping Anti-Obesity Medications Gain Back Pounds at a Quadrupled Rate Compared to People Using Diet and Exercise Obesity treatment often requires ongoing approaches. A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who halt conventional diet and exercise programs. Findings released in a prominent health publication points out that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Users using these medications must be cognizant of the danger of fast weight regain when the medication ends," stated expert Dr. Susan Jebb. That rate of recovery means a reversion to starting mass within about 18 months. Weighing Therapies The analysis, which examined 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods. Scientists emphasize that people who lose weight through diet and exercise typically experience a slower creep back—around 0.1 kg a month—after stopping. Understanding the Rapid Rebound Nutrition scientists propose the way of the jabs accounts for the amplified weight return. The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating much more probable." A Lifelong Issue? The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. A number of clinicians say that, considering the significant potential of relapse, the treatment is often life-long. This perspective is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of excess weight," akin to managing conditions like diabetes. User Experiences People who have come off the jabs describe a sudden return of cravings. "I experienced a trigger flipping and you're instantly ravenous," said an individual. This difficulty is exacerbated if individuals have not established permanent dietary or behavioural modifications during treatment. Widespread Interest Figures show that a significant number of people in the UK have used these injections in the last 12 months, with desire remaining high. Use is more common among females than men. The 40s and 50s age group shows the highest usage rates. Many access the medications through private prescriptions rather than the NHS. In conclusion, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and maintained weight loss relies on combined behavioural changes.
Obesity treatment often requires ongoing approaches. A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who halt conventional diet and exercise programs. Findings released in a prominent health publication points out that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Users using these medications must be cognizant of the danger of fast weight regain when the medication ends," stated expert Dr. Susan Jebb. That rate of recovery means a reversion to starting mass within about 18 months. Weighing Therapies The analysis, which examined 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods. Scientists emphasize that people who lose weight through diet and exercise typically experience a slower creep back—around 0.1 kg a month—after stopping. Understanding the Rapid Rebound Nutrition scientists propose the way of the jabs accounts for the amplified weight return. The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating much more probable." A Lifelong Issue? The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes. A number of clinicians say that, considering the significant potential of relapse, the treatment is often life-long. This perspective is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of excess weight," akin to managing conditions like diabetes. User Experiences People who have come off the jabs describe a sudden return of cravings. "I experienced a trigger flipping and you're instantly ravenous," said an individual. This difficulty is exacerbated if individuals have not established permanent dietary or behavioural modifications during treatment. Widespread Interest Figures show that a significant number of people in the UK have used these injections in the last 12 months, with desire remaining high. Use is more common among females than men. The 40s and 50s age group shows the highest usage rates. Many access the medications through private prescriptions rather than the NHS. In conclusion, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and maintained weight loss relies on combined behavioural changes.